➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Moodys
Johnson and Johnson
Harvard Business School
AstraZeneca

Last Updated: May 28, 2020

DrugPatentWatch Database Preview

Lederle Company Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for LEDERLE, and what generic and branded alternatives to LEDERLE drugs are available?

LEDERLE has ninety-six approved drugs.



Summary for Lederle
US Patents:0
Tradenames:49
Ingredients:48
NDAs:96

Drugs and US Patents for Lederle

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lederle PROCAINAMIDE HYDROCHLORIDE procainamide hydrochloride CAPSULE;ORAL 086952-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Lederle PROBENECID probenecid TABLET;ORAL 086917-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Lederle AMITRIPTYLINE HYDROCHLORIDE amitriptyline hydrochloride TABLET;ORAL 086746-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Lederle CHLORDIAZEPOXIDE HYDROCHLORIDE chlordiazepoxide hydrochloride CAPSULE;ORAL 087231-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Lederle RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HYDROCHLORIDE hydralazine hydrochloride; hydrochlorothiazide; reserpine TABLET;ORAL 087709-001 May 13, 1982 DISCN No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Lederle

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lederle ASENDIN amoxapine TABLET;ORAL 018021-004 Approved Prior to Jan 1, 1982 3,663,696   Start Trial
Lederle ASENDIN amoxapine TABLET;ORAL 018021-001 Approved Prior to Jan 1, 1982 3,681,357   Start Trial
Lederle ASENDIN amoxapine TABLET;ORAL 018021-001 Approved Prior to Jan 1, 1982 3,546,226   Start Trial
Lederle ASENDIN amoxapine TABLET;ORAL 018021-004 Approved Prior to Jan 1, 1982 3,546,226   Start Trial
Lederle ASENDIN amoxapine TABLET;ORAL 018021-002 Approved Prior to Jan 1, 1982 3,681,357   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for LEDERLE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe for Oral Suspension 500 mg/5 mL ➤ Subscribe 2014-07-22
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
AstraZeneca
Moodys
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.